Drug intelligence / Profile preview

EVP-6308

Development stage: Phase 1
Lead developer: FORUM Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

EVP-6308 is a novel, highly potent, and selective small molecule inhibitor of phosphodiesterase 10A (PDE10A), developed by FORUM Pharmaceuticals (formerly EnVivo Pharmaceuticals). PDE10A is an enzyme that regulates the levels of cyclic nucleotides cAMP and cGMP in the striatum, which are important for signaling mechanisms in the striatal-cortical network and cognitive function. By inhibiting PDE10A, EVP-6308 modulates these pathways and has been investigated as a potential treatment for schizophrenia—specifically targeting positive symptoms, negative symptoms, and cognitive impairments. The drug reached Phase 1 clinical trials but development was discontinued for schizophrenia[1][3][5][6][9].

Other names: FRM 6308FRM6308FRM-6308

Targets

PDE10A (Phosphodiesterase 10A)

Beyond the preview

Go deeper on EVP-6308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVP-6308.

Explore the full profile